Drug Trial Radar · NCT04716114
A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated
Last checked: Nov 19, 2026Latest source record: Nov 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
315
Planned (sponsor's estimate)
Start
Mar 24, 2021
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized,multicenter, open-label Phase III, clinical study to confirm the efficacy and safety of SKLB1028 in patients with relapsed or refractory(R/R) FLT3-Mutated Acute Myeloid Leukemia(AML)compared to salvage chemotherapy.
Conditions
- Acute Myeloid Leukemia (AML)
Interventions
SKLB1028Drug
SKLB1028 will be administered by oral capsules, 150 mg twice daily (BID).
Salvage ChemotherapyDrug
Low-dose cytarabine (LoDAC); azacytidine; homoharringtonine (HHT), cytarabine and aclarubicin (HAA) or fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) will be administered by subcutaneous (SC) and/or intravenous (IV) injections.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Interim analysis: CR/CRh rate in the experimental group.Time frame: up to 4 years.
- The final analysis: Overall Survival(OS)Time frame: up to 4 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.